Association of mu-opioid receptor expression with lymph node metastasis in esophageal squamous cell carcinoma

Diseases of the Esophagus

Volumn 28, Issue 2, 2015, Pages 196-203

  Zhang, Y F ^a   Xu, Q X ^a   Liao, L D ^a   Xu, X E ^a   Wu, J Y ^a   Wu, Z Y ^b   Shen, J H ^b   Li, E M ^a   Xu, L Y ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b SHANTOU CENTRAL HOSPITAL   (China)

Author keywords

ESCC; GPCR; Survival; opioid receptor

Indexed keywords

MU OPIATE RECEPTOR; OPRM1 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA CELL; CELL MEMBRANE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; WESTERN BLOTTING; AGED; DISEASE COURSE; ESOPHAGUS TUMOR; METABOLISM; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTORS, OPIOID, MU; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84923515416     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12165     Document Type: Article

References (39)

1. Zadina J E, Kastin A J, Ge L J, Hackler L. Mu, delta, and kappa opiate receptor binding of Tyr-MIF-1 and of Tyr-W-MIF-1, its active fragments, and two potent analogs. Life Sci 1994; 55: L461-466.
2. Trescot A M, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11: S133-153.
3. Mantyh P W. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006; 7: 797-809.
4. Chaturvedi K, Christoffers K H, Singh K, Howells R D. Structure and regulation of opioid receptors. Biopolymers 2000; 55: 334-346.
5. Martini L, Whistler J L. The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 2007; 17: 556-564.
6. Xu J, Xu M, Rossi G C, Pasternak G W, Pan Y X. Identification and characterization of seven new exon 11-associated splice variants of the rat mu opioid receptor gene, OPRM1. Mol Pain 2011; 7: 9-22.
7. Kasai S, Ikeda K. Pharmacogenomics of the human micro-opioid receptor. Pharmacogenomics 2011; 12: 1305-1320.
8. Cadet P, Rasmussen M, Zhu W, Tonnesen E, Mantione K J, Stefano G B. Endogenous morphinergic signaling and tumor growth. Front Biosci 2004; 9: 3176-3186.
9. Fichna J, Janecka A. Opioid peptides in cancer. Cancer Metastasis Rev 2004; 23: 351-366.
10. Mathew B, Lennon F E, Siegler J etal. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011; 112: 558-567.
11. Lennon F E, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton P A. Overexpression of the mu-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology 2012; 116: 857-867.
12. Afsharimani B, Cabot P, Parat M O. Morphine and tumor growth and metastasis. Cancer Metastasis Rev 2011; 30: 225-238.
13. Bovill J G. Surgery for cancer: does anesthesia matter? Anesth Analg 2010; 110: 1524-1526.
14. Lennon F E, Moss J, Singleton P A. The mu-opioid receptor in cancer progression: is there a direct effect? Anesthesiology 2012; 116: 940-945.
15. Jemal A, Bray F, Center M M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
16. Zhang Y F, Xu Q X, Liao L D etal. Kappa-opioid receptor in the nucleus is a novel prognostic factor of esophageal squamous cell carcinoma. Hum Pathol 2013; 44: 1756-1765.
17. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer 1992; 69: 277-284.
18. Cancer Institute of the Chinese Academy of Medical Sciences (CICAMS). Establishment of an epithelial cell line from human esophageal carcinoma. Chin Med J 1976; 2: 357-364.
19. Zhang F R, Tao L H, Shen Z Y, Lv Z, Xu L Y, Li E M. Fascin expression in human embryonic, fetal, and normal adult tissue. J Histochem Cytochem 2008; 56: 193-199.
20. Gach K, Piestrzeniewicz M, Fichna J, Stefanska B, Szemraj J, Janecka A. Opioid-induced regulation of mu-opioid receptor gene expression in the MCF-7 breast cancer cell line. Biochem Cell Biol 2008; 86: 217-226.
21. Zylla D, Gourley B L, Vang D etal. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 2013; 119: 4103-4110.
22. Lu J, Liu Z, Zhao L, Tian H, Liu X, Yuan C. In vivo and in vitro inhibition of human liver cancer progress by downregulation of the mu-opioid receptor and relevant mechanisms. Oncol Rep 2013; 30: 1731-1738.
23. Nylund G, Pettersson A, Bengtsson C, Khorram-Manesh A, Nordgren S, Delbro D S. Functional expression of mu-opioid receptors in the human colon cancer cell line, HT-29, and their localization in human colon. Dig Dis Sci 2008; 53: 461-466.
24. Gach K, Szemraj J, Stasikowska-Kanicka O, Danilewicz M, Janecka A. Opioid-receptor gene expression and localization in cancer cells. Cent Eur J Biol 2011; 6: 10-15.
25. Fang W K, Liao L D, Li L Y etal. Down-regulated desmocollin-2 promotes cell aggressiveness through redistributing adherens junctions and activating beta-catenin signalling in oesophageal squamous cell carcinoma. J Pathol 2013; 231: 257-270.
26. Chen Y L, Law P Y, Loh H H. The other side of the opioid story: modulation of cell growth and survival signaling. Curr Med Chem 2008; 15: 772-778.
27. Minnis J G, Patierno S, Kohlmeier S E, Brecha N C, Tonini M, Sternini C. Ligand-induced mu opioid receptor endocytosis and recycling in enteric neurons. Neuroscience 2003; 119: 33-42.
28. Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 2000; 156: 567-575.
29. Gach K, Szemraj J, Fichna J, Piestrzeniewicz M, Delbro D S, Janecka A. The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line. Chem Biol Drug Des 2009; 74: 390-396.
30. Gobeil F, Fortier A, Zhu T etal. G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol 2006; 84: 287-297.
31. Kieffer B L, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 2002; 66: 285-306.
32. Lee H J, Lee J H, Lee E O etal. Substance P and beta endorphin mediate electroacupuncture induced analgesic activity in mouse cancer pain model. Acupunct Electrother Res 2009; 34: 27-40.
33. Bortsov A V, Millikan R C, Belfer I, Boortz-Marx R L, Arora H, McLean S A. μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 2012; 116: 896-902.
34. Boehncke S, Hardt K, Schadendorf D, Henschler R, Boehncke W H, Duthey B. Endogenous-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol 2011; 20: 24-28.
35. Dai X, Cui S G, Wang T, Liu Q, Song H J, Wang R. Endogenou opioid peptides, endomorphin-1 and -2 and deltorphin I stimulate angiogenesis in the CAM assay. Eur J Pharmaco 2008; 579: 269-275.
36. Gupta K, Kshirsagar S, Chang L etal. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62: 4491-4498.
37. Dai X, Song H J, Cui S G, Wang T, Liu Q, Wang R. The stimulative effects of endogenous opioids on endothelial cell proliferation, migration and angiogenesis in vitro. Eur J Pharmacol 2010; 628: 42-50.
38. Farooqui M, Geng Z H, Stephenson E J, Zaveri N, Yee D, Gupta K. Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Mol Cancer Ther 2006; 5: 611-620.
39. Singleton P A, Lingen M W, Fekete M J, Garcia J G, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res 2006; 72: 3-11.